Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model – HDP-101 in Refractory Multiple Myeloma report and make more profitable business decisions.

This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.


HDP-101 in Refractory Multiple Myeloma Drug Details:

HDP-101 is under development for the treatment of relapsed/refractory multiple myeloma. The therapeutic candidate constitutes a BCMA antibody targeting CD269 antigen conjugated to amanitin. It is administered through intravenous route.  It is being developed based on Amanitin ATAC technology.The drug candidate was also under development for diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukaemia (CLL).

Report Coverage

The data is segmented by drug name per indication and shows the current likelihood of approval for the drug compared to the indication benchmark and the industry benchmark.

The Likelihood of Approval data is updated regularly based on events that take place which impact the clinical development process and regulatory considerations. GlobalData’s proprietary machine learning models consider these events in real time, to produce quantitative changes to the LOA and PTSR along with qualitative reasoning why the likelihood of approval has changed.

Scope of Report

  • Drug Details: Drug name, Drug type, Intervention type
  • Administration Pathway
  • Therapeutic Areas
  • Key Manufacturers
  • Drug Development Status

Reasons to buy

  • Precise Likelihood of Approval and Phase Transition Success Rates: Our machine learning and proprietary models provide accurate predictions, helping you gauge the potential success of a drug in the regulatory process.
  • Competitive Strategy Planning: Access information on LOA and PTSR for competitors’ drugs, allowing you to plan your clinical development, commercialisation and marketing strategies
  • Event-driven Updates: Track event-driven changes in LOA and PTSR benchmarked against indication LOA/PTSR. Get the latest insights to adapt your strategies promptly!
  • Well-informed Investment Decisions: This data helps you navigate the dynamic landscape of drug development and regulatory considerations.

What our clients have to say

More Reports

View More Reports